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cure. They acknowledge the lack of data and the patients’ de-
sire for intensive surveillance but argue that the resources
should be better used for optimal adjuvant treatment and
mammography, which definitely lead to increased survival,
and not for surveillance strategies of uncertain benefit.
The contradicting argumentations are not new but will lead to
ever new, yet inconclusive discussions as long as there is no
new evidence in the context of modern diagnostics and treat-
ment modalities. While the lack of new evidence cannot be a
persuasive excuse for indefinitely keeping old, maybe obso-
lete standards, it also should not lead to new surveillance
strategies of hypothetical character. The global community of
breast cancer care providers has the responsibility to design
and perform new, much warranted trials on this subject. The
Breast Commission of the German ‘Arbeitsgemeinschaft Gy-
näkologische Onkologie’ is currently designing a randomized
trial comparing intensified versus conventional breast cancer
surveillance. Both patients and doctors hope that this and
other trials will be implemented soon and will yield new evi-
dence. As long as results of these studies are pending, the
standard, however, should remain unchanged.
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One of the most frequently asked questions from patients
after the completion of primary treatment for early breast
cancer is whether the treatment was successful after all. Due
to the lack of adequate monitoring tools, doctors are not only
without a reliable basis for answering this question at the time
of primary treatment, but have to face the same insecurity as
the patient herself for the coming years of follow-up. There-
fore, both patients and doctors are in desperate need for bet-
ter monitoring tools for the follow-up of breast cancer patients
than are currently available.
In their editorial, Siegfried Seeber and Anja Welt [1] point out
that the evidence for not including tumor markers and imag-
ing diagnostics (with the exception of mammography) into the
routine of routine follow-up is far from solid and beyond
doubt. They convincingly argue that the design of the two Ital-
ian randomized trials was not optimal and that novel and suc-
cessful treatment options for metastatic breast cancer were
not available during the 1980s, when these studies were per-
formed. The authors conclude that the lack of benefit from in-
tensified surveillance that was demonstrated more than 20
years ago cannot be a sufficient reason for denying intensified
surveillance and early detection of metastatic disease nowa-
days. They picture scenarios in which the early detection and
treatment of oligometastatic disease might lead to long-term
remission.
Jennifer Griggs and Daniel Hayes [2], on the other hand,
stress the fact that early detection of asymptomatic metastatic
disease has never been shown to lead to a higher likelihood of
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